Triazines - Adverse effects
Research News and Information

Sunday, November 22, 2009

Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.

30 Aug 2009 BACKGROUND: We report the case of a 16-year-old male with Mucopolysaccharidosis III type A (Sanfilippo syndrome) who was commenced on risperidone for behaviour management. He rapidly developed extrapyramidal symptoms that have not resolved. METHOD: ... Read more...

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients.

30 Aug 2009 BACKGROUND: Severe cutaneous adverse reactions (SCARs) are associated with over 200 medicines including lamotrigine, an antiepileptic drug. Previous studies have suggested the involvement of immune mechanisms in the development of drug-induced ... Read more...

The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?

30 Aug 2009 Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures. Before the emergence of the newer antiepileptic ... Read more...

Latest indexed articles for 'Triazines - Adverse effects'

These are the very latest articles for this heading:

• Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. 30 Aug 2009
• High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. 30 Aug 2009
• The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? 30 Aug 2009
• Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. 9 Aug 2009
• End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. 27 Jul 2009
• Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. 16 Jun 2009
• Melamine-contaminated powdered formula and urolithiasis. 16 Jun 2009
• Melamine-contaminated powdered formula and urolithiasis. 16 Jun 2009
• Melamine exposure assessment in children with nephrolithiasis. 8 Jun 2009
• Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. 30 May 2009
• A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. 30 May 2009
• Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? 30 May 2009
• By the way, doctor. Finasteride has been prescribed for my BPH. I think that the most frequent side effect is erectile dysfunction or loss of sexual desire. Would Levita or a similar drug (like Viagra or Cialis) overcome the side effects of finasteride? 30 May 2009
• Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. 26 May 2009
• Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. 10 May 2009
• Levitra for sphincter of Oddi dysfunction? Are you kidding? 29 Apr 2009
• Vardenafil: efficacy, tolerability and future directions. 29 Apr 2009
• Lamotrigine-induced aseptic meningitis: a case report. 29 Apr 2009
• Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. 14 Apr 2009
• [Anticonvulsant hypersensitivity syndrome and lamotrigine-associated anticonvulsant hypersensitivity syndrome] 9 Apr 2009

See a longer list of these articles.

Technical information about 'Triazines'

Definition: Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.

Registry Number: 0

Descriptor UI: D014227

Alternative terms: Triazines; Benzotriazines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D03.383.931;

Technical Notes: do not confuse with TRIAZENES